Evaluation of novel highly specific antibodies to cancer testis antigen Centrin-1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer.
Rubin JiaoKevin J H AllenMackenzie E MaloMuath HelalZewei JiangKarishma SmartSusan V BuhlDavid RicklesRuth A BryanEkaterina DadachovaPublished in: Cancer medicine (2019)
The results demonstrate the ability of these novel antibodies to detect CETN1 both in vitro and in vivo; as well, the RIT treatment of experimental PDAC when radiolabeled with 213 Bi is highly efficient and safe. Further evaluation of these novel reagents for diagnosis and treatment of PDAC is warranted.